NEWS 86 FEED & ADDITIVE MAGAZINE August 2022 Blue Ocean Barns completes $20 million Series A financing Hawaii-based Agricultural technology company Blue Ocean Barns completed a $20 million Series A funding round, enabling the company to dramatically expand farming and commercial adoption of Brominata™, its seaweed-based digestive aid for cattle. The Series A round, led by Valor Siren Ventures, includes Tao Capital Partners and strategic investors. The funding brings Blue Ocean Barns' total capital raised to nearly $27 million. Blue Ocean Barns will use the funding to expand the company's tank-based farming, harvesting, and processing operations. Within the next four years, Blue Ocean Barns and its food company partners are poised to surpass three million tons of net CO2-equivalent emissions reductions annually from one million cows, growing to 100 million cows by the end of the decade. Feeding a sprinkling of Brominata daily to only the dairy cows in the state of California – less than 2% of U.S. cattle -- will have the same annual climate impact as Tesla's global fleet last year. The all-natural seaweed, which Blue Ocean Barns' business model ensures is made available at no cost to farmers, has been shown in published research and on-farm trials to safely eliminate more than 80 percent of cows' methane production without changing the taste of milk or meat. Earlier this year, the company was granted authorization to sell Brominata in California by the state's Department of Food and Agriculture. In addition, the US Patent and Trademark Office allowed a plant patent for Blue Ocean Barns' Brominata, the first ever such patent for a variety of algae or seaweed. Blue Ocean Barns was first to market globally with a safe seaweed digestive aid. Zoetis Inc. appointed Vanessa Broadhurst, Executive VP, Global Corporate Affairs at Johnson & Johnson, to its Board of Directors. Broadhurst has deep experience in consumer insights and direct-to-consumer advertising, and her appointment increases the size of the Board from 11 to 12 members. She will serve on the Board’s Quality and Innovation Committee. Broadhurst is a member of Johnson & Johnson’s Executive Committee and leads the company’s global marketing, communication, design and philanthropy functions, in addition to having oversight of Johnson & Johnson Health & Wellness Solutions. Prior to her appointment to the Executive Committee in 2022, Ms. Broadhurst was Company Group Chairman, Global Commercial Strategy for Pharmaceuticals. Broadhurst was named one of the “2022 Most Influential Black Executives in Corporate America” by SAVOY magazine. She has also been recognized as “Healthcare Champion of the Year” by the National Association for Female Executives, and “Top Blacks in Healthcare” by Blackdoctors.org. Zoetis appoints Vanessa Broadhurst to its Board of Directors Vanessa Broadhurst
RkJQdWJsaXNoZXIy MTUxNjkxNQ==